NurExone Biologic Inc. (NRX V) stock market data APIs
C$0.6636
0(0%)
as of May 16, 2025
Try our APIs with
free plan!
NurExone Biologic Inc. Financial Data Overview
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. Its technology includes ExoPTEN, for acute spinal cord injury, and glaucoma; and Exosomes, nature's guided missiles for regeneration and healing for specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Prev. Close
0.6636
Open
0.6636
High
0.6636
Low
0.6564
52 wk Range
0.46-0.87
Market Cap
51 485 K
Shares Outstanding
78 008 K
EPS
-0.02
Beta
0.018
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NurExone Biologic Inc. data using free add-ons & libraries
Get NurExone Biologic Inc. Fundamental Data
NurExone Biologic Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -4 951 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-09
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NurExone Biologic Inc. News
New
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its...
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released...
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thril...
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
